ReviewFrontiers in genetics2020
Genetic Diagnosis of Familial Hypercholesterolemia in Asia.
Review in Frontiers in genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia.BioMed research international · 2021 · on this mapPooled it
- Effects of Familial Hypercholesterolemia on Major Adverse Cardiac and Cerebrovascular Events in Patients with Premature Coronary Artery Disease: A Retrospective Cohort Study.Research in heart yield and translational medicine · 2025Article
- Prevalence and factors associated with possible cases of familial hypercholesterolemia in Brazilian adults: a cross-sectional study.Scientific reports · 2023Article
- Article
- Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.The American journal of case reports · 2023Article
- TheInternational journal of environmental research and public health · 2022Article
- Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia.Journal of atherosclerosis and thrombosis · 2022Article
- Familial Hypercholesterolaemia in the Malaysian Community: Prevalence, Under-Detection and Under-Treatment.Journal of atherosclerosis and thrombosis · 2021Article
- Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.JACC. Asia · 2021Article
- Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia.Endocrinology and metabolism (Seoul, Korea) · 2021Article
- Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial hypercholesterolemia (FH) is a common genetic disease with an incidence of about 1 in 200-500 individuals. Genetic mutations markedly elevate low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease (ASCVD) in FH patients. With advances in clinical diagnosis and genetic testing, more genetic mutations have been detected, including those in low-density lipoprotein receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.